Maria J. Lallena

Madrid, MD 28108, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing.

Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing.

Journal: International journal of molecular sciences

Published: February 04, 2025

Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer.

Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer.

Journal: Cancer research

Published: July 24, 2024

Survival benefit from abemaciclib in non-small cell lung cancer by Kirsten rat sarcoma-mutation gene expression subtype: retrospective analysis from the JUNIPER Trial.

Survival benefit from abemaciclib in non-small cell lung cancer by Kirsten rat sarcoma-mutation gene expression subtype: retrospective analysis from the JUNIPER Trial.

Journal: Frontiers in oncology

Published: July 08, 2024

High-Throughput DNA-Encoded Libraries Affinity Selection Platform for Binder Identification with Solid Support Protein Immobilization.

High-Throughput DNA-Encoded Libraries Affinity Selection Platform for Binder Identification with Solid Support Protein Immobilization.

Journal: Assay and drug development technologies

Published: April 19, 2024

Design, synthesis and validation of a new Crimped Head-Piece for DNA-Encoded libraries generation.

Design, synthesis and validation of a new Crimped Head-Piece for DNA-Encoded libraries generation.

Journal: Bioorganic & medicinal chemistry

Published: October 13, 2023

TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling.

TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling.

Journal: Molecular oncology

Published: September 11, 2023

Author Correction: Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy.

Author Correction: Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy.

Journal: NPJ breast cancer

Published: December 28, 2022

Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy.

Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy.

Journal: NPJ breast cancer

Published: April 11, 2022

Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation.

Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation.

Journal: Oncotarget

Published: March 17, 2022

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells.

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells.

Journal: Oncotarget

Published: November 04, 2019

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).

Journal: Bioorganic & medicinal chemistry letters

Published: June 27, 2019

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.

Journal: Molecular cancer therapeutics

Published: May 15, 2018

Showing 1-12 of 21

Last Updated: 09/26/2026